/Insulet%20Corporation%20insulin%20monitor-by%20Maria%20Wan%20via%20Shutterstock.jpg)
With a market cap of $18.4 billion, Insulet Corporation (PODD) is a leading developer of innovative insulin delivery systems for people with insulin-dependent diabetes. The company's flagship product, the Omnipod System, offers a tubeless, wearable insulin pump with wireless capabilities, providing a discreet and easy-to-use solution for continuous insulin delivery.
Companies valued at more than $10 billion are generally classified as “large-cap” stocks, and Insulet fits this criterion perfectly. Headquartered in Acton, Massachusetts, Insulet also partners with pharmaceutical and biotechnology companies to expand the application of its technology for the delivery of other subcutaneous drugs.